Home
Clinical Trials
IBI3009-101

IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

Short Title: IBI3009-101

Enrollment Status: Recruiting

NCT #: NCT06613009

Specialty Area: Oncology

Condition Studied: Small Cell Lung Cancer

Age Groups: Adult; Older Adult

Phase: I

Study Information

Summary / Purpose

To find out if IBI3009 is safe and well-tolerated, and to determine the best dose to use in future studies for people with advanced small cell lung cancer.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with small cell lung cancer that cannot be removed with surgery (unresectable) or has spread to other places in the body (metastatic) or extensive-stage
Adequate organ function
No major surgery within 4 weeks prior to the first dose of the study medication or while participating in the study

What's Involved

Participation in the study will include:

Treatment with an investigational medication called IBI3009
Dose adjustments to find the safest and most effective amount of the medication
Physical exams
Electrocardiograms (ECGs) to measure heart function
Blood tests
Questionnaires

Principal Investigator

Katharine Thomas, MD

Oncology

A Member of

(775) 982–2820

Renown Hematology/Oncology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06613009

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews